There really seems to be no apatite for this stock any longer. What happened to the B-12 deficient patient study? Isn't it at least 18 months late now? At least that have a marketing agreement for B-12 (in vitamins). I don't really have an revenue expectation for this though. Especially when there is (at least as far as I can tell) any transparency to the deal. What are the getting, anything? Who knows. What premium is the list price for the vitamin? What revenue was Life Extension getting for B-12? Will they market normal and Eligen side by side? Has Life Extension done any market study to project revenue? Way too many questions.